Literature DB >> 17191049

Scleromyxedema: successful treatment with thalidomide in two patients.

Mona Amini-Adle1, Nadege Thieulent, Stéphane Dalle, Brigitte Balme, Luc Thomas.   

Abstract

BACKGROUND: Scleromyxedema is an unusual skin disease characterized by mucinous infiltration of the skin. There is no satisfactory treatment for this disorder. CASE REPORT: We report 2 cases of scleromyxedema, both associated with an IgG-lambda paraprotein. Treatment with thalidomide was started and great improvement of the lesion was noted as shown by a quality of life questionnaire similar to those used in rheumatoid arthritis. TNF-alpha value was elevated in both cases during this treatment. DISCUSSION: We hypothesize that the efficiency of thalidomide could be mediated by its costimulatory effect on T cytotoxic lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17191049     DOI: 10.1159/000096914

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  3 in total

1.  [Scleromyxedema. A chronic progressive systemic disease].

Authors:  A Kreuter; M Stücker; A G A Kolios; P Altmeyer; K Möllenhoff
Journal:  Z Rheumatol       Date:  2012-08       Impact factor: 1.372

Review 2.  Scleroderma-like fibrosing disorders.

Authors:  Francesco Boin; Laura K Hummers
Journal:  Rheum Dis Clin North Am       Date:  2008-02       Impact factor: 2.670

3.  Scleromyxedema with subcutaneous nodules: successful treatment with thalidomide and intravenous immunoglobulin.

Authors:  M Dolenc-Voljč; V Jurčić; A Hočevar; M Tomšič
Journal:  Case Rep Dermatol       Date:  2013-11-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.